ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2023

CONCORD, Mass., June 20, 2023--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that two abstracts were accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2023, taking place in Vienna, Austria June 21 - 24, 2023.

Related Keywords

Australia ,Vienna ,Wien ,Austria ,Melbourne ,Victoria ,United States ,America ,Aileen Rubio ,Stephen Locarnini ,Chris Stevens ,Jennifer Locke ,Asia Pacific ,Aditi Deshpande ,Clearb Therapeutics Inc ,Good Laboratory Practice ,Victoria Infectious Diseases Reference Laboratory ,International Liver Congress ,Clearb Therapeutics ,European Association ,Austria June ,Morningside Ventures ,Professor Stephen Locarnini ,North America ,Chief Operating ,